DCF Advisers LLC Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

DCF Advisers LLC grew its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,507 shares of the biopharmaceutical company’s stock after purchasing an additional 3,650 shares during the period. Intra-Cellular Therapies comprises approximately 3.5% of DCF Advisers LLC’s holdings, making the stock its 5th largest holding. DCF Advisers LLC owned approximately 0.10% of Intra-Cellular Therapies worth $6,884,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Intra-Cellular Therapies by 1.4% in the first quarter. Vanguard Group Inc. now owns 9,225,981 shares of the biopharmaceutical company’s stock valued at $638,438,000 after purchasing an additional 131,679 shares during the period. Wasatch Advisors LP raised its position in Intra-Cellular Therapies by 6.3% during the 1st quarter. Wasatch Advisors LP now owns 3,854,747 shares of the biopharmaceutical company’s stock valued at $266,748,000 after purchasing an additional 227,439 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Intra-Cellular Therapies by 9.7% in the 1st quarter. Avoro Capital Advisors LLC now owns 2,475,000 shares of the biopharmaceutical company’s stock worth $171,270,000 after buying an additional 219,445 shares during the period. Clearbridge Investments LLC grew its position in shares of Intra-Cellular Therapies by 12.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock worth $120,723,000 after buying an additional 191,416 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Intra-Cellular Therapies during the fourth quarter valued at $85,744,000. 92.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on ITCI shares. The Goldman Sachs Group lowered their price objective on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Mizuho increased their price objective on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, June 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a research note on Monday. UBS Group dropped their target price on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Piper Sandler raised Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $68.00 to $92.00 in a research report on Friday, September 6th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, Intra-Cellular Therapies has an average rating of “Moderate Buy” and a consensus target price of $96.58.

Insider Buying and Selling at Intra-Cellular Therapies

In other news, Director Rory B. Riggs sold 4,462 shares of Intra-Cellular Therapies stock in a transaction on Monday, June 24th. The shares were sold at an average price of $75.57, for a total transaction of $337,193.34. Following the completion of the sale, the director now directly owns 116,600 shares in the company, valued at $8,811,462. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Sharon Mates sold 34,396 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $77,962,764.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rory B. Riggs sold 4,462 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $75.57, for a total value of $337,193.34. Following the completion of the transaction, the director now directly owns 116,600 shares of the company’s stock, valued at approximately $8,811,462. The disclosure for this sale can be found here. In the last quarter, insiders have sold 179,778 shares of company stock worth $13,374,538. 3.40% of the stock is owned by corporate insiders.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $76.97 on Friday. The stock’s fifty day moving average price is $75.68 and its 200 day moving average price is $71.37. Intra-Cellular Therapies, Inc. has a 1-year low of $45.50 and a 1-year high of $84.89. The company has a market cap of $8.13 billion, a price-to-earnings ratio of -66.35 and a beta of 1.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.03. The firm had revenue of $161.40 million for the quarter, compared to the consensus estimate of $157.74 million. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. The company’s revenue for the quarter was up 45.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.45) earnings per share. As a group, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.